Public universities can be negatively affected during a government shutdown — especially within its research department. Miguel Tovar/University of Houston

As the partial government shutdown loomed, academic institutions explored ways this might affect their research operations. Although we expect delays in processing proposals and award payouts, the impact on the institution may have been much less than expected. Consequently, most of the impact occurred at the individual principal investigator, or PI, level. That is where research that required federal resources came to a halt.

This is also the case for researchers at the Borders, Trade, and Immigration (BTI) Institute at the University of Houston. As a result of the shutdown, they were unable to start any new projects. Sadly, the government furloughed their program manager at the Department of Defense- Science and Technology Office of University Programs.

Education initiatives and multiple other research projects pending review were stuck along the "assembly line," as approvals did not happen during the month of January.

Consequently, BTI is a granted institution. Current projects were able to continue with slight delay due to the requirement to have meetings with the DHS representatives for their projects.

This scenario echoed across the research enterprise, as other researchers found themselves in similar situations.

Business as somewhat usual

Moreover, Nicholas Bond, climatologist and associate professor of atmospheric sciences at the University of Washington, felt the pinch of the shutdown and chronicled his experiences of how it impacted his research on climate and oceanography of the North Pacific.

Academic institutions across the country became burdened with the task of assuming unexpected financial responsibilities. In mid-January, the lapse in governmental funding forced The Ohio State University to temporarily cover the costs of unbilled expenditures to the tune of about $3 million. Harvard University continued to pay stipends for fellowships. They did this despite the fact that the shutdown included the federal funding agency.

Many faculty members, including our own, were able to continue working on their projects with the expectation of administrative delays. No new funding opportunities were issued, panel reviews were postponed and no new grants or no-cost extensions were awarded. For the most part, it was business as (somewhat) usual.

The big picture

It may be safe to say that the partial shutdown acted more as an inconvenience to the research enterprise than anything. Which is great news! Especially for the University of Houston, who has recently ignited the campus with the announcement of the 50-in-5 initiative. This ambitious program will increase the research and scholarly output by 50 percent over the next five years.

While this article focuses on the inconvenience of administrative delays, it's critical not to skim the surface. It may seem minute when compared to recipients of public assistance fearing not receiving benefits, but short-term implications are likely.

Keep in mind that most often, grants are not awarded by a single payment from the agency. Timelines are established between agencies and the institutions, and funds are released accordingly. Because of this, it's likely that research programs and educational initiatives across the academic research enterprise will not receive their funds on schedule.

What the future holds

Imagine, if you will, a conveyor belt. A system designed to allow items to move through a process with maximum efficiency. Because of the partial shutdown, research proposals that were in queue for review or funding experienced interruption along the conveyor belt.

Once disruptions to processes within federal agencies happen, it becomes inevitable that there will be delays further down the line.

Claudia Neuhauser, associate vice chancellor/vice president for Research and Technology Transfer for the UH System, warns of the "ripple effect" of the downstream delays and the potential impact on expenditures. We'll have to wait until the end of the year when annual reports are prepared for answers.

For now, it's a question of what the aftereffect will be.

------

This article originally appeared on the University of Houston's The Big Idea.

Nitiya Spearman is the internal communications coordinator for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.